NCT03961009View on ClinicalTrials.gov

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

December 21, 2020

Study Completion Date

December 21, 2020

Conditions
Primary Immunodeficiency Disease
Interventions
BIOLOGICAL

Kedrion IVIG 10%

Kedrion intravenous immunoglobulin (IVIg) 10%

Trial Locations (11)

14203

University of Buffalo, Buffalo

33408

Allergy Associates of the Palm Beaches, North Palm Beach

43235

Optimed Research, Columbus

43617

Toledo Institute of Clinical Research Inc, Toledo

44124

Ohio Clinical Research Associates, Inc., Mayfield Heights

55446

Midwest Immunology Clinic and Infusion Center, Plymouth

60612

Rush University Medical Center, Chicago

66211

Dr. Henry J. Kanarek - Allergy, Asthma & Immunology, Overland Park

75230

Allergy Partners of North Texas Research, Dallas

75231

AARA Research Center, Dallas

07739

Allergy and Immunology Associates, Little Silver

All Listed Sponsors
lead

Kedrion S.p.A.

INDUSTRY

NCT03961009 - Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients | Biotech Hunter | Biotech Hunter